Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA

BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneous autoinjector (SC-AI) as a weekly starting ...
Scientific Research Publishing

Overcoming Financial Barriers for SMEs and Startups in the DRC: Leveraging Digital Financial Services for an Effective Entrepreneurial Ecosystem ()

The Access, Usage, and Quality framework, rooted in financial inclusion theory, provides a robust structure for analyzing how DFS and crowdfunding expand access, improve usage rates, and enhance ...